Individuals who may warrant closer monitoring include: Those with a personal or family history of depression , anxiety, or other mood disorders People who have previously experienced mood changes on other weight-loss medications or GLP-1-based therapies Individuals with eating disorders or a complex relationship with food , for whom appetite suppression may have psychological implications (see NICE guideline NG69: Eating disorders: recognition and treatment) [10] Those experiencing significant life stressors alongside starting a new treatment People with poorly controlled type 2 diabetes , where fluctuating blood glucose levels both hypoglycaemia and hyperglycaemia can independently affect mood, concentration, and emotional wellbeing It is also worth acknowledging that obesity itself is associated with higher rates of depression and anxiety, and that the psychological experience of rapid body weight change whether positive or negative can be emotionally complex
This is the DermaVue clinical protocol developed across several thousand GLP-1 patients
This dual approach could theoretically offer a more complete strategy for improving metabolic health, especially for individuals facing significant challenges with obesity, insulin resistance, or age-related metabolic decline
Most clients describe the sensation as a brief pinch that lasts only a second or two
This guarantees that the medication you receive is authentic, properly stored, and handled according to stringent guidelines, ensuring the highest quality and efficacy
Gastroenterology, 98(6), 14521459
